Results 91 to 99 of about 31,974 (99)
Some of the next articles are maybe not open access.
Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
Journal of Clinical Oncology, 2009 P. Bhargava, B. Esteves, D. Nosov, O. Lipatov, A. A. Lyulko, A. Anischenko, R. Chacko, P. Lee, M. Al-Adhami, J. Ryan +9 moresemanticscholar +1 more sourceEpidemiological, clinical characteristics and outcome of severe scorpion envenomation in South Tunisia: multivariate analysis of 951 cases.
Toxicon, 2008 M. Bouaziz, M. Bahloul, H. Kallel, M. Samet, H. Ksibi, H. Dammak, Mohamed Ahmed, K. Chtara, H. Chelly, C. Hamida, N. Rekik +10 moresemanticscholar +1 more sourceGalileo Encounter with 951 Gaspra: First Pictures of an Asteroid
Science, 1992 M. Belton, J. Veverka, P. Thomas, P. Helfenstein, D. Simonelli, C. Chapman, M. Davies, R. Greeley, Richard Greenberg, J. Head, S. Murchie, K. Klaasen, T. Johnson, A. McEwen, D. Morrison, G. Neukum, F. Fanale, C. Anger, M. Carr, C. Pilcher +19 moresemanticscholar +1 more sourceActivity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).
, 2010 P. Bhargava, B. Esteves, M. Al-Adhami, D. Nosov, O. Lipatov, A. A. Lyulko, A. Anischenko, R. Chacko, D. Doval, W. Slichenmyer +9 moresemanticscholar +1 more source